[Systemic lupus erythematosus. Target criteria for treatment].

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease.
• SLE affects nearly all organ systems and is identified by over 100 auto-antibodies.
• Effective management necessitates clear criteria for evaluating therapeutic outcomes.

Purpose of the Study:

• To highlight the necessity of defining target criteria for assessing SLE therapy effectiveness.
• To review available instruments for measuring SLE disease activity and impact.
• To discuss the role of biomarkers in characterizing SLE pathophysiology and prognosis.

Main Methods:

• Review of existing instruments for disease activity, quality of life, and organ damage assessment in SLE.
• Discussion of various biomarkers for characterizing SLE.
• Analysis of criteria for evaluating therapeutic effectiveness in clinical practice and studies.

Main Results:

• Multiple instruments exist to measure SLE disease activity, quality of life, irreversible damage, and organ-specific manifestations.
• Biomarkers are available to characterize pathophysiologic aspects, clinical activity, therapeutic effectiveness, and prognosis of SLE.
• Defining target criteria is crucial for evaluating SLE treatment efficacy.

Conclusions:

• Standardized criteria and validated instruments are essential for evaluating SLE treatment efficacy.
• Biomarkers offer valuable insights into SLE's multifaceted nature, aiding in prognosis and treatment monitoring.
• Further research into robust biomarkers and criteria will improve SLE patient care.